氧化铁纳米颗粒在肺癌治疗中可能发挥重要作用。通过植物介导合成、化学合成和微生物介导合成三种方法合成了氧化铁纳米颗粒（NPs）。通过X射线衍射（XRD）、傅里叶变换红外光谱（FTIR）、场发射扫描电子显微镜（FE-SEM）、映射和电泳电位等方法对合成的氧化铁纳米颗粒进行了表征。通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基-2H-四唑溴化物（MTT）测定了Fe2O3@PEG@CDDP、Fe2O3@PEG和CDDP对A549和HFF细胞的细胞毒性。在2,2'-阿齐诺基（3-乙基苯并噻唑啉-6-磺酸）（ABTS）和2,2-联苯基-1-萘酰肼（DPPH）测定中，Fe2O3@PEG@CDDP、Fe2O3@PEG和CDDP的抗氧化剂清除活性分别显示了IC50值（11.96，26.74和3.17 μg/ml）和（8.54，11.4和1.14 μg/ml）。植物介导合成法得到的纳米颗粒表现出了很高的抗氧化活性。结果表明，绿色方法合成的纳米颗粒对于杀死癌细胞是最有效的。因此，绿色合成的纳米颗粒的特性比其他方法更有价值。绿色合成是一种环保、经济和简单的纳米颗粒合成方法。版权所有 © 2023. Elsevier B.V. 发布。

Iron oxide nanoparticles could play a useful role in lung cancer therapy. Iron oxide nanoparticles (NPs) were synthesized by plant mediated synthesis, chemical, and microbial mediated synthesis. iron oxide nanoparticle polyethylene glycol cis-diamminedichloroplatinum (Fe2O3@PEG@CDDP(, iron oxide nanoparticle polyethylene glycol (Fe2O3@PEG), and cis-diamminedichloroplatinum (CDDP) were evaluated for their antioxidant,and in vitro cytotoxicity tests. X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), Field emission scanning electron microscopy (FE-SEM), mapping, and zeta potential were used to characterize the synthesized iron oxides NPs. Cell toxicity was determined using A549 and HFF cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. The antioxidant scavenging activity of Fe2O3@PEG@CDDP, Fe2O3@PEG, and CDDP displayed IC50 values (11.96, 26.74, and 3.17 μg/ml) and (8.54, 11.4, and 1.14 μg/ml) in 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and 2,2-Diphenyl-1-picrylhydrazyl (DPPH) assays, respectively. Nanoparticles obtained from plant mediated synthesis method showed the great antioxidant activity. Results showed that, green-method synthesized nanoparticles were the most effective at killing cancer cells. Thus, the characteristics of nanoparticles from green synthesis are more valuable than the other methods. Green synthesis is environmental friendly cost-effective, and easy approach for synthesize NPs.Copyright © 2023. Published by Elsevier B.V.